CRL News and Press, Charles River Laboratories International Inc. From 04/09/24

2024-04-09 10:48:26 ET More on Charles River Laboratories Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold' Charles River Laboratories International, Inc. (CRL) Q4 2023 Earnings Call Transcript Charles River brokers gene therapy ...

HQ plasmid DNA production to support Phase I trials for gene therapy targeting Bardet-Biedl Syndrome Charles River Laboratories International, Inc. (NYSE: CRL) today announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration with Axovia Therapeuti...

GMP grade plasmid DNA to serve as a direct therapeutic targeting various indications Charles River Laboratories International, Inc. (NYSE: CRL) and Ship of Theseus , a therapeutics company developing degradation-resistant homeobox (HOX) family biologics, today announced a Good Manuf...

2024-04-01 13:41:12 ET BofA analysts published “the most neglected” stocks -- or least crowded -- within each of the 11 sectors of the S&P 500 ( SP500 ).... Read the full article on Seeking Alpha For further details see: These are the most neglected sto...

Researchers highlight translational services to optimize drug development programs Charles River Laboratories International, Inc. (NYSE: CRL) announced today that its industry-leading team of oncology experts will attend the American Association for Cancer Research (AACR) Annual Meeti...

ESG progress includes $200M investment in alternative testing methods; achievement of 92% renewable energy usage worldwide Charles River Laboratories International, Inc. (NYSE: CRL) today announced the publication of its 2023 Corporate Citizenship Report , which includes progress an...

Collaboration provides phase-appropriate plasmid DNA to support the development of engineered stem cells for cancer therapy Charles River Laboratories International, Inc. (NYSE: CRL) and National University of Singapore’s (NUS) Yong Loo Lin School of Medicine (NUS Medicin...

2024-03-15 22:14:17 ET Summary Ariel Investments' 13F portfolio value increased from $9.45B to $10.04B in Q4 2023. The largest five stakes in the portfolio are Jones Lang LaSalle, Mattel, Generac Holdings, Carlyle Group, and Charles River Laboratories. Stake increases were see...

2024-03-14 10:27:07 ET More on Charles River Laboratories Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold' Charles River Laboratories International, Inc. (CRL) Q4 2023 Earnings Call Transcript DURECT and Charles River enter agre...

Next-generation AAV gene therapy to target debilitating pain disorders Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics , Inc., a biotechnology company developing epigenetic gene therapies, today announced an AAV9 production program agreement. As pa...